STATUS OF THE CLAIMS

1.-16. (Cancelled).

17. (Currently Amended) A method of treating ~~viral or bacterial infections, inflammatory diseases, or~~ a tumor comprising tumor cells which express Hsp70 on their cell surface, said method comprising:

(a) administering a pharmaceutical composition consisting essentially of a pharmaceutically effective amount of isolated granzyme B as the only pharmaceutically active component to ~~cells affected by said infection or inflammatory diseases or~~ tumor cells, said tumor ~~target~~ cells bearing Hsp70 on their surface;

(b) allowing granzyme B to enter said cells via Hsp70 on the surface of said cells; and

(c) allowing said cells to undergo apoptosis as a result of the enzymatic activity of granzyme B.

18-24. (Cancelled).

25. (Previously Presented) The method of claim 17, wherein granzyme B is present in the pharmaceutical composition in a final concentration of 1μg/ml to 500μg/ml.

26. (Previously Amended) The method of claim 17, wherein granzyme B is present in the pharmaceutical composition in a final concentration of 1ng/ml to 10 ng/ml.

27. (Previously Amended) The method of claim 26 wherein granzyme B is present in the pharmaceutical composition in a final concentration of about 6 ng/ml.

28. (Cancelled).

29. (Currently Amended) A method of treating ~~viral or bacterial infections, inflammatory diseases or~~ a tumor comprising tumor cells which express Hsp70 on their cell surface, said method comprising:

(a) analyzing ~~target~~ tumor cells of a patient for surface expression of Hsp70;

(b) administering a pharmaceutical composition comprising a pharmaceutically effective amount of granzyme B to ~~cells affected by said infection or inflammation or~~ said tumor cells, said cells bearing Hsp70 on their surface;

(c) allowing granzyme B to enter said cells via Hsp70 on the cell surface; and

(d) allowing said cells to undergo apoptosis as a result of the enzymatic activity of granzyme B.

30. (Previously Presented) The method of claim 29, wherein granzyme B is present in the pharmaceutical composition in a final concentration of 1μg/ml to 500μg/ml.

31. (Previously Presented) The method of claim 29, wherein granzyme B is present in the pharmaceutical composition in a final concentration of 1ng/ml to 10 ng/ml.

32. (Previously Presented) The method of claim 31 wherein granzyme B is present in the pharmaceutical composition in a final concentration of about 6 ng/ml.

33. (Cancelled)